P-glycoprotein-mediated efflux of antiepileptic drugs: preliminary studies in mdr1a knockout mice.
about
A multi-system approach assessing the interaction of anticonvulsants with P-gpDrug-Resistant Epilepsy: Multiple Hypotheses, Few AnswersDrug resistance in brain diseases and the role of drug efflux transporters.Phenobarbital for the treatment of epilepsy in the 21st century: a critical review.Therapeutic implications of the MDR-1 gene.Potential role of drug transporters in the pathogenesis of medically intractable epilepsy.Drug resistance in epilepsy: putative neurobiologic and clinical mechanisms.Use of biopartitioning micellar chromatography and RP-HPLC for the determination of blood-brain barrier penetration of α-adrenergic/imidazoline receptor ligands, and QSPR analysis.Toward the prediction of CNS drug-effect profiles in physiological and pathological conditions using microdialysis and mechanism-based pharmacokinetic-pharmacodynamic modeling.Drug transporters in the epileptic brain.Multidrug resistance in epilepsy: a pharmacogenomic update.The emerging importance of transporter proteins in the psychopharmacological treatment of the pregnant patient.The blood-brain barrier in migraine treatment.Drug interactions at the blood-brain barrier: fact or fantasy?Drug transporters: gatekeepers controlling access of xenobiotics to the cellular interior.The right compound in the right assay at the right time: an integrated discovery DMPK strategy.The intrinsic severity hypothesis of pharmacoresistance to antiepileptic drugs.Development of individualized medicine for epilepsy based on genetic information.Effect of Oxidative Stress on ABC Transporters: Contribution to Epilepsy Pharmacoresistance.The pharmacokinetics of commonly used antiepileptic drugs in immature CD1 miceIn vitro transport profile of carbamazepine, oxcarbazepine, eslicarbazepine acetate, and their active metabolites by human P-glycoprotein.The multidrug transporter hypothesis of refractory epilepsy: corroboration and contradiction in equal measure.Antiepileptic drug transport--of mice and men.Use of verapamil as a potential P-glycoprotein inhibitor in a patient with refractory epilepsy.A comparative study of the effect of carbamazepine and valproic acid on the pharmacokinetics and metabolic profile of topiramate at steady state in patients with epilepsy.A pilot study on brain-to-plasma partition of 10,11-dyhydro-10-hydroxy-5H-dibenzo(b,f)azepine-5-carboxamide and MDR1 brain expression in epilepsy patients not responding to oxcarbazepine.Classification analysis of P-glycoprotein substrate specificity.Population pharmacokinetics of gabapentin in healthy Korean subjects with influence of genetic polymorphisms of ABCB1.Inhibition of the multidrug transporter P-glycoprotein improves seizure control in phenytoin-treated chronic epileptic rats.Phenytoin carried by silica core iron oxide nanoparticles reduces the expression of pharmacoresistant seizures in rats.Lack of association between the C3435T polymorphism in the human multidrug resistance (MDR1) gene and response to antiepileptic drug treatment.
P2860
Q28533527-6B506CC9-8D92-473A-9337-ABF2267807FBQ33875271-766D9070-E45C-4AAA-A509-DDE62369AD0FQ33988704-69DD8309-13E9-4F32-9DCD-3A7FFD162E43Q34343308-44DB2BCF-C94C-4646-8AC5-068745AED8FBQ35925779-07C87F55-C47E-44F2-A412-0AF211EF7BBBQ36023613-E3A184FB-E617-437C-9F66-5B1AD0282900Q36157234-30AE2DD9-7101-4CE8-A6F6-AA87849CE0E6Q36319277-7FE3DAC2-318C-4D99-94D0-3414392046C0Q36341660-3940815D-E65D-41E5-8095-40838D78B45CQ36742736-C550AECD-A325-4479-AB7D-423E6764A465Q36895830-6625BA79-E1E2-46B0-B8CF-6505FCF883C9Q37024001-5154EF43-C63E-4598-8A69-DEBC837B7BAEQ37252452-BD84FB1C-EF46-4A39-BD53-74C31946A99EQ37362486-3C2FB874-C8F2-4F48-BB93-3B88F16C2D1BQ37514340-A18CF733-E1BF-411E-BB54-5E14ECE498CEQ38018653-F1701058-B1EA-452A-B688-F657E2A4C896Q38104378-D800B945-2B7A-4568-A17D-44DEC8E70ED2Q38178326-354C1F30-1BEB-493B-9C42-B5905639EEE8Q39164058-A79ECCC7-59A0-4CE0-BE91-50A541D6F68AQ39233929-3EC06CFE-A689-4754-BA10-CC64129BCA60Q39520772-3A1B6422-6FDD-4163-9ED7-7635AD14EF7CQ42153282-B3CCDF14-C548-442B-94B1-AF7A60E80A40Q43073437-5E1BBA73-7D30-4A97-908E-F21960FB2551Q45029801-DBC1AB75-D8F4-4C49-A223-87AE116462EEQ46606251-3ABF9F0A-BD20-4743-A541-520BF32200E7Q46725875-BDF58B52-9809-4D92-A44B-5FE13B2EA16EQ47326688-45EC7BAE-A503-4CB4-934F-81B5C49E14AFQ47822510-4FBFB4C2-0A69-4D7A-BC92-1DA0360727C8Q48560275-47F37715-4E06-45C0-9A65-899D25623235Q51613858-E70DC4B2-F00A-45B7-A9D0-57F538662E19Q53859498-9DA5FD15-FBA9-4509-B600-CB8A8B38D2EA
P2860
P-glycoprotein-mediated efflux of antiepileptic drugs: preliminary studies in mdr1a knockout mice.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
P-glycoprotein-mediated efflux ...... tudies in mdr1a knockout mice.
@en
P-glycoprotein-mediated efflux ...... tudies in mdr1a knockout mice.
@nl
type
label
P-glycoprotein-mediated efflux ...... tudies in mdr1a knockout mice.
@en
P-glycoprotein-mediated efflux ...... tudies in mdr1a knockout mice.
@nl
prefLabel
P-glycoprotein-mediated efflux ...... tudies in mdr1a knockout mice.
@en
P-glycoprotein-mediated efflux ...... tudies in mdr1a knockout mice.
@nl
P2093
P50
P1433
P1476
P-glycoprotein-mediated efflux ...... studies in mdr1a knockout mice
@en
P2093
Elaine Butler
Graeme J. Sills
Martin J. Brodie
P304
P356
10.1016/S1525-5050(02)00511-5
P577
2002-10-01T00:00:00Z